The premiere CD44 targeting clinical stage oncology and arthritis company.

Splash Pharmaceuticals, Inc. ("Splash") is a clinical stage oncology and arthritis company with a novel strategy to target CD44 safely and effectively. Splash has decades of experience, data, and know-how in many cancer indications and arthritis. The lead candidate, SPL-108, has demonstrated promising safety and efficacy in multiple clinical trials in over 100 human subjects.

For partnering or other information, please contact us at david@splashpharma.com.